Premedication Strategy for Weekly Paclitaxel
Authors:
- 1 January 2002
- journal article
- Published by Taylor & Francis in Cancer Investigation
- Vol. 20 (5-6) , 666-672
Abstract
Purpose: Dexamethasone and histamine antagonists have been employed commonly as premedications for prophylaxis of hypersensitivity reactions (HSRs) to paclitaxel. Frequent premedications for weekly administration of paclitaxel are associated with added side-effects and extra cost. We analyzed our experience of HSRs to paclitaxel administered every 3–4 weeks, and designed a treatment algorithm to eliminate premedications in a majority of patients receiving weekly paclitaxel. Patients and methods: The incidence of HSRs was analyzed retrospectively in patients who received 3-hr infusions of paclitaxel (135–225 mg/m2) every 3–4 weeks in our institution over a period of 5 years. On the basis of the results of this analysis, we designed a premedication schema for patients receiving weekly paclitaxel, 50–90 mg/m2/week, as follows: Thirty minutes prior to the first weekly dose of paclitaxel, patients received intravenously (IV) dexamethasone (10 mg), diphenhydramine (25 mg), and cimetidine (300 mg). If no HSRs occurred, all premedications were deleted for subsequent weekly paclitaxel doses. For patients who experienced HSRs, 20 mg of dexamethasone was given orally 12 and 6 hr prior to re-challenge with paclitaxel in addition to diphenhydramine and cimetidine. Results: Over a period of 5 years, 358 patients received 1608 3-hr infusions of paclitaxel (135–225 mg/m2). Hypersensitivity reactions, which occurred exclusively during the first cycle of paclitaxel administration, were observed in 14 patients. Of these 14 patients, 11 were successfully retreated with paclitaxel without HSRs, two had recurrent HSRs upon paclitaxel re-challenge, and one refused further treatment. These observations indicate that HSRs to paclitaxel occurred in 4% of patients upon first exposure, that most of these patients can be retreated successfully with paclitaxel without recurrent HSRs, and that if no HSRs occur during the first cycle, HSRs are unlikely to occur with subsequent paclitaxel administration. The premedication schema was applied to 30 patients receiving 205 one-hr infusions of weekly paclitaxel. Using this premedication strategy, no HSRs have been observed during the initial or subsequent administration of paclitaxel. Conclusion: We conclude that this premedication strategy is feasible and worthy of further study for patients receiving weekly paclitaxel.Keywords
This publication has 8 references indexed in Scilit:
- Twice-Weekly Paclitaxel and Weekly Carboplatin With Concurrent Thoracic Radiation Followed by Carboplatin/Paclitaxel Consolidation for Stage III Non–Small-Cell Lung Cancer: A California Cancer Consortium Phase II TrialJournal of Clinical Oncology, 2001
- Paclitaxel-Associated Hypersensitivity Reactions: Experience of the Gynecologic Oncology Program of the Cleveland Clinic Cancer CenterJournal of Clinical Oncology, 2000
- Paclitaxel (Taxol): An Inhibitor of Angiogenesis in a Highly Vascularized Transgenic Breast CancerCancer Biotherapy and Radiopharmaceuticals, 1999
- Multiinstitutional phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer.Journal of Clinical Oncology, 1998
- Taxol Hypersensitivity: Rapid Retreatment Is Safe and Cost EffectiveGynecologic Oncology, 1998
- Severe lymphocytopenia and interstitial pneumonia in patients treated with paclitaxel and simultaneous radiotherapy for non-small-cell lung cancer.Journal of Clinical Oncology, 1996
- Phase I trial of outpatient weekly paclitaxel and concurrent radiation therapy for advanced non-small-cell lung cancer.Journal of Clinical Oncology, 1994
- Hypersensitivity reactions from taxol.Journal of Clinical Oncology, 1990